Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotech company specializing in mRNA cell therapy for autoimmune diseases, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event, scheduled for May 20, 2024, at 3:00 p.m. ET, will feature a live fireside chat with the company’s management team. The webcast will be available on the company's website for a time.

Positive

• Participation in a significant investor conference like H.C. Wainwright's 2nd Annual BioConnect can boost visibility and investor interest in Cartesian Therapeutics (RNAC).
• The live webcast provides accessibility to a broader audience, potentially attracting new investors.
• The focus on mRNA cell therapy for autoimmune diseases positions Cartesian Therapeutics in a high-potential, innovative market.

Negative

• No new clinical or financial data was presented, which might leave investors wanting more substantial updates.
• The webcast's availability may restrict the long-term visibility of the event's content.

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.

A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the event will be accessible for a limited time.

About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information
Investor Relations:
Ron Moldaver
Ron.moldaver@cartesiantx.com

Media:
David Rosen
Argot Partners
cartesian@argotpartners.com

FAQ

What is the significance of Cartesian Therapeutics (RNAC) participating in the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

Participation in this conference can enhance Cartesian Therapeutics' visibility and attract potential investors through a live fireside chat with management.

When will Cartesian Therapeutics (RNAC) present at the H.C. Wainwright BioConnect Investor Conference?

Cartesian Therapeutics will present on May 20, 2024, at 3:00 p.m. ET.

How can I access the live webcast of Cartesian Therapeutics' presentation?

The live webcast will be available in the Events section of Cartesian Therapeutics' website.

Will there be an archived replay of Cartesian Therapeutics' presentation at the H.C. Wainwright BioConnect Investor Conference?

Yes, an archived replay of the event will be accessible on Cartesian Therapeutics' website for a time.